VanEck Pharmaceutical ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
VanEck Pharmaceutical ETF PPH
Morningstar’s Analysis PPH
Will PPH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 71.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 20.79 | 212M | Healthcare |
Merck & Co Inc | 13.33 | 136M | Healthcare |
Novo Nordisk AS ADR | 5.59 | 57M | Healthcare |
Pfizer Inc | 5.14 | 53M | Healthcare |
Bristol-Myers Squibb Co | 4.85 | 50M | Healthcare |
Teva Pharmaceutical Industries Ltd | 4.77 | 49M | Healthcare |
McKesson Corp | 4.61 | 47M | Healthcare |
GSK PLC ADR | 4.44 | 45M | Healthcare |
Cencora Inc | 4.38 | 45M | Healthcare |
AbbVie Inc | 3.64 | 37M | Healthcare |